Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 35,355 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Postoperative Pain
Interventions: TENS Unit; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Risk Perceptions, Decision Making, Alcohol
Interventions: Health warning statement evaluations (bottles), Health warning statement evaluations (ads); Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Depression, Suicide Ideation
Interventions: ketamine; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: CMV, AdV Infection, AdV Reactivation, Adenovirus, Cytomegalovirus Infections
Interventions: Standard of Care Antiviral medications, Viral CTLs; Drug · Biological
Lead sponsor: New York Medical College; Other
Eligibility: 1 Day to 30 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Valhalla, New York • Milwaukee, Wisconsin

Conditions: Typhoid
Interventions: Dose of 5.0 x 10^9 CFU (Cohort 1), Dose of 7.5 x 10^9 CFU (Cohort 2), Dose of 1.1 x 10^10 CFU (Cohort 3), Dose of of 1.7 x 10^10 CFU (Cohort 4), Placebo (Cohorts 1-4 pooled); Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 187 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: South Miami, Florida • Baltimore, Maryland • Burlington, Vermont

Conditions: Glaucoma, Primary Open Angle
Interventions: NT-501 CNTF Implant; Drug
Lead sponsor: Jeffrey L Goldberg; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Coronary Artery Disease
Interventions: Stenting plus OMT, OMT, Standard of care; Other
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 21 Years and older
Enrollment: 1,170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 6
States / cities: Palo Alto, California • Stanford, California • Atlanta, Georgia + 3 more

Conditions: Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes
Interventions: Metformin HCl and Colesevelam Placebo, Metformin HCl tablets and Colesevelam tablets, Colesevelam placebo, Colesevelam; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Gatos, California • Tarzana, California + 14 more

Conditions: Influenza
Interventions: Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Healthy Volunteers, no Condition, Basic Science
Interventions: Transcranial Focused Ultrasound Stimulation, Electroencephalography, Magnetic Resonance Imaging; Device
Lead sponsor: Massachusetts Institute of Technology; Other
Eligibility: 21 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Anterior Cruciate Ligament Injury
Interventions: Operant Conditioning, Control, Single Pulse Transcranial Magnetic Stimulation; Behavioral · Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 45 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Ovarian Cancer, Adnexal Mass
Interventions: Method 1: Indocyanine green dye, Method 2: Indocyanine green dye, Method 3: Indocyanine green dye; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Warts
Interventions: Resiquimod; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 10
States / cities: Jonesboro, Arkansas • San Francisco, California • Longmont, Colorado + 7 more

Conditions: Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction
Interventions: Brimonidine 0.15%, Brimonidine 0.075%, Placebo; Drug
Lead sponsor: Sandeep Jain, MD; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Cervical Cancer
Interventions: GSK1120212 (trametinib), GSK2141795; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis B
Interventions: INO-1800, INO-9112, Nucleos(t)ide Analogue Treatment; Biological · Drug
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 7
States / cities: San Diego, California • Miami, Florida • Manhasset, New York + 4 more

Conditions: Hypertension, Resistant to Conventional Therapy
Interventions: Placebo - 1st Cycle, MANP - 1st Cycle, MANP - 2nd Cycle; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 20 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Dietary Modification, Cardiovascular Risk Factor
Interventions: MeLT Dietary intervention, TLC Dietary intervention, MeLT dietary intervention with TMAO; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Colon Cancer Stage III, Colon Cancer Stage IV
Interventions: HVLA cervical chiropractic adjustments; Procedure
Lead sponsor: Life University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Wellness, Health
Interventions: Ubiquinol + geranylgeraniol, Geranylgeraniol, Ubiquinol, Ubiquinone, Placebo; Dietary Supplement · Other
Lead sponsor: OvationLab; Network
Eligibility: 40 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 6
States / cities: El Dorado Hills, California • Centennial, Colorado • Palm Springs, Florida + 3 more

Conditions: Healthy, no Evidence of Disease
Interventions: Akt inhibitor SR13668; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 62 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Allergic Asthma
Interventions: Placebo, Omalizumab, Immunotherapy; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Neuroblastoma
Interventions: irinotecan hydrochloride, vincristine sulfate, iobenguane I 131; Drug · Radiation
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 1 Year to 30 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 12
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more

Conditions: Seasonal Influenza
Interventions: mRNA-1010, Fluarix Quadrivalent; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 22,502 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 134
States / cities: Athens, Alabama • Glendale, Arizona • Phoenix, Arizona + 110 more

Search by objective public record fields.

Evaluating Transcutaneous Electrical Nerve Stimulation for Postoperative Pain After Video-Assisted Thoracotomy Surgery

Designing Effective Alcohol Health Warnings: An Experimental Study With Adults in the U.S.

Ketamine for Low Mood States in the ER

Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone

Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement

FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT

Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.

Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines

Transcranial Ultrasonic Neuromodulation of Primary Visual Cortex and Primary Auditory Cortex in Humans

Conditioning Brain Responses to Improve Thigh Muscle Function After Anterior Cruciate Ligament Reconstruction

ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study

Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)

GSK1120212+GSK2141795 for Cervical Cancer

Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects

MANP in African Americans With Hypertension

Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)

The Effects of Chiropractic in Adults With Colon Cancer

Comparing the Effects of Commercially Available Dietary Supplements on CoQ10 Concentrations

Studying Different Formulations of SR13668 in Healthy Volunteers

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older